BTC health announces exclusive distribution agreement with Exstent

BTC health Ltd (ASX: $BTC) has announced that its investee company, BTC Cardio Pty Ltd, has secured exclusive distribution rights for the ExoVasc® Personalised External Aortic Root Support (PEARS) medical device from Exstent Limited. The agreement forecasts sales revenue of approximately $700K in the first year, with planned annual growth of 10-15%.

Executive Commentary on Exclusive Distribution Agreement

Dr Richard Treagus, Executive Chairman of BTC health, expressed his enthusiasm, stating, 'ExoVasc is a highly innovative solution, and a strong complimentary fit with our rapidly expanding presence in the cardiothoracic space. We are proud to be offering this as an alternative surgical solution, which truly has the potential to change patients' lives.' Victoria Sharpe, Managing Director of Exstent, also commented, 'We believe BTC Cardio is the right partner to further grow sales of the ExoVasc® in Australia, and offering patients a choice of treatment for aortic dilatation.'

Summary of Exclusive Distribution Agreement and Outlook

BTC health's announcement of the exclusive distribution agreement with Exstent Limited for the ExoVasc® PEARS medical device marks a significant milestone in the company's expansion in the cardiothoracic space. The agreement grants BTC Cardio Pty Ltd exclusive rights to sell and distribute the innovative medical device, with forecasted sales revenue of approximately $700K in the first year and planned annual growth of 10-15%. The ExoVasc® device, designed to manage aortic dilation in individuals with Marfan syndrome and related genetic conditions, has demonstrated its effectiveness with over 1000 patients having received the support. BTC Cardio's assumption of full responsibility for ExoVasc® and its sponsorship of the Marfan and Aortopathy Conference in Brisbane reflect the company's commitment to providing alternative surgical solutions and supporting medical advancements. Dr Richard Treagus' positive outlook on the potential impact of ExoVasc® and Victoria Sharpe's confidence in BTC Cardio's capabilities further underline the strategic significance of this agreement for BTC health's corporate strategy and its goal of offering access to innovative medical products.